Current Status: M4
Graduate Department: Immunology and Molecular Pathogenesis
Previous Education: History, Yale University;
Hometown: Ann Arbor, MI
Reading, Running, Socializing, and Baking
The standard of care for patients with congenital hemophilia A is the infusion of recombinant or plasma-derived factor VIII (fVIII). Approximately 30% of patients develop detectable inhibitory anti-fVIII antibodies (inhibitors) in response to these infusions, which is the most serious complication in the treatment of hemophilia A. In addition, non-hemophiliacs can break tolerance to their native fVIII protein. We have characterized the diversity of the immune response against fVIII using a murine hemophilia A model and are presently focusing on preventing the development of the inhibitors.